Is lamivudine with one-week HBIg as effective as long-term high dose HBIg in the HBV prophylaxis after liver transplantation?

2001 ◽  
Vol 34 ◽  
pp. 2 ◽  
Author(s):  
Sang-Jong Park ◽  
Seung Woon Paik ◽  
Moon Seok Choi ◽  
Joon Hyeok Lee ◽  
Kwang Cheol Koh ◽  
...  
2019 ◽  
Vol 80 (10) ◽  
pp. 594-599
Author(s):  
Roger W Chapman ◽  
Richard J Aspinall ◽  
Palak Trivedi ◽  
Gavin Wright ◽  
Michael Heneghan

Autoimmune hepatitis is widely assumed by health-care professionals to be a disease that is easily controlled through the use of corticosteroids and immunosuppressants but recent studies in the UK indicate highly variable treatment regimens and often unsatisfactory treatment outcomes, such as dependence on long-term high-dose steroids and ongoing need for liver transplantation in some cases. The therapeutic use of the systemically acting corticosteroid prednisolone results in unacceptable side effects in many patients. Recent evidence suggests that it is not always necessary to use high-dose steroids (>0.5 mg/kg/d) to attain remission; and side effects may also be minimised through more targeted therapy with the less systemically-absorbed corticosteroid, budesonide. The authors offer advice on the stratification of treatment for these patients and suggest changes to improve the services available for people with autoimmune hepatitis in the UK.


2019 ◽  
Vol 17 (Sup10) ◽  
pp. S30-S36
Author(s):  
Roger W Chapman ◽  
Richard J Aspinall ◽  
Palak Trivedi ◽  
Gavin Wright ◽  
Michael Heneghan

Autoimmune hepatitis is widely assumed by health-care professionals to be a disease that is easily controlled through the use of corticosteroids and immunosuppressants but recent studies in the UK indicate highly variable treatment regimens and often unsatisfactory treatment outcomes, such as dependence on long-term high-dose steroids and ongoing need for liver transplantation in some cases. The therapeutic use of the systemically acting corticosteroid prednisolone results in unacceptable side effects in many patients. Recent evidence suggests that it is not always necessary to use high-dose steroids (>0.5 mg/kg/d) to attain remission; and side effects may also be minimised through more targeted therapy with the less systemically-absorbed corticosteroid, budesonide. The authors offer advice on the stratification of treatment for these patients and suggest changes to improve the services available for people with autoimmune hepatitis in the UK.


2020 ◽  
Vol 13 (9) ◽  
pp. e235777 ◽  
Author(s):  
Jeffrey Spindel ◽  
Matthew Heckroth ◽  
Luis Marsano

Autoimmune encephalitis is a rare spectrum of disease that can be a complication of chronic immunosuppression. Diagnosis often requires the presence of antineuronal antibodies, but many causative antibodies have not yet been identified. Antibody-negative autoimmune encephalitis (AbNAE) is especially difficult to diagnose and must rely largely on exclusion of other causes. In chronically immune-suppressed transplant recipients, the differential is broad, likely resulting in underdiagnosis and worse outcomes. Here, we present a 58-year-old liver transplant recipient taking tacrolimus for prevention of chronic rejection who presented with 5 days of confusion, lethargy and lightheadedness. He was diagnosed with AbNAE after an extensive workup and recovered fully after high-dose corticosteroids. Our case highlights the importance of recognising the association between chronic immunosuppression and autoimmune encephalitis. Autoimmune encephalitis, even in the absence of characterised antibodies, should be considered when transplant recipients present with central neurologic symptoms.


2002 ◽  
Vol 34 (4) ◽  
pp. 1252-1254 ◽  
Author(s):  
S.-J Park ◽  
S.W Paik ◽  
M.S Choi ◽  
J.H Lee ◽  
K.C Koh ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document